(Q33388653)

26 July 2017

Multicentre phase II study of CyclOBEAP plus rituximab in patients with diffuse large B-cell lymphoma (English)

1 reference

multicenter clinical trial

26 July 2017

0 references

B-cell lymphoma

1 reference

diffuse large B-cell lymphoma

inferred from title

1 reference

1 reference

Nozomi Niitsu

1

1 reference

26 July 2017

Mika Kohri

2

1 reference

26 July 2017

Yuki Hagiwara

3

1 reference

26 July 2017

Ken Tanae

4

1 reference

26 July 2017

Naoki Takahashi

5

1 reference

26 July 2017

Masami Bessho

6

1 reference

26 July 2017

Masataka Okamoto

7

1 reference

26 July 2017

1 June 2010

1 reference

26 July 2017

Hematological Oncology

1 reference

26 July 2017

28

1 reference

26 July 2017

2

1 reference

26 July 2017

68-74

1 reference

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

26 July 2017

1 reference

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project

21 January 2018

1 reference

7 January 2021

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

7 January 2021

Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma

1 reference

7 January 2021

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60).

1 reference

7 January 2021

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

1 reference

7 January 2021

Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.

1 reference

7 January 2021

Multicenter phase II study of the CyclOBEAP (CHOP-like + etoposide and bleomycin) regimen for patients with poor-prognosis aggressive lymphoma

1 reference

7 January 2021

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

1 reference

7 January 2021

Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy.

1 reference

7 January 2021

Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma

1 reference

7 January 2021

Revised response criteria for malignant lymphoma

1 reference

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

7 January 2021

Individual Comparisons by Ranking Methods

1 reference

7 January 2021

Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma

1 reference

7 January 2021

Upfront double high-dose chemotherapy with DICEP followed by BEAM and autologous stem cell transplantation for poor-prognosis aggressive non-Hodgkin lymphoma

1 reference

7 January 2021

Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study

1 reference

7 January 2021

Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers

1 reference

7 January 2021

Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo I

1 reference

7 January 2021

Identifiers

DOI

10.1002/HON.940

1 reference

26 July 2017

1 reference